Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Goyal RK, et al. Among authors: huang yj. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):699-710. doi: 10.1080/14737167.2020.1804871. Epub 2020 Sep 14. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32755262
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM. Rugo HS, et al. Among authors: huang yj. Breast Cancer Res Treat. 2020 Nov;184(1):161-172. doi: 10.1007/s10549-020-05838-5. Epub 2020 Aug 12. Breast Cancer Res Treat. 2020. PMID: 32789591 Free PMC article.
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Cuyun Carter G, Sheffield KM, Gossai A, Huang YJ, Zhu YE, Bowman L, Nash Smyth E, Mathur R, Cohen AB, Rasmussen E, Balakrishna S, Morato Guimaraes C, Rybowski S, Seidman AD. Cuyun Carter G, et al. Among authors: huang yj. Curr Med Res Opin. 2021 Jul;37(7):1179-1187. doi: 10.1080/03007995.2021.1923468. Epub 2021 May 20. Curr Med Res Opin. 2021. PMID: 33970738
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL, Sudharshan L, Ryan P, Rajkumar J, Sheffield KM, Nash Smyth E, Morato Guimaraes C, Rybowski S, Cuyun Carter G, Gathirua-Mwangi WG, Huang YJ. Price GL, et al. Among authors: huang yj. Curr Med Res Opin. 2022 Aug;38(8):1319-1331. doi: 10.1080/03007995.2022.2073122. Epub 2022 May 13. Curr Med Res Opin. 2022. PMID: 35535675
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M, Takada M, Nakayama T, Masuda N, Shiheido H, Cai Z, Huang YJ, Kawaguchi T, Tanizawa Y. Kawai M, et al. Among authors: huang yj. Breast Cancer Res Treat. 2023 Jan;197(2):435-447. doi: 10.1007/s10549-022-06816-9. Epub 2022 Nov 21. Breast Cancer Res Treat. 2023. PMID: 36414795 Free PMC article.
1,562 results